Gilead Sciences Inc. (GILD): Price and Financial Metrics
GET POWR RATINGS... FREE!
GILD Price/Volume Stats
Current price | $77.09 | 52-week high | $89.74 |
Prev. close | $77.65 | 52-week low | $57.17 |
Day low | $77.01 | Volume | 5,439,000 |
Day high | $78.62 | Avg. volume | 5,829,345 |
50-day MA | $80.90 | Dividend yield | 3.86% |
200-day MA | $78.01 | Market Cap | 96.16B |
GILD Stock Price Chart Interactive Chart >
GILD POWR Grades
- GILD scores best on the Value dimension, with a Value rank ahead of 97.46% of US stocks.
- The strongest trend for GILD is in Sentiment, which has been heading down over the past 179 days.
- GILD ranks lowest in Momentum; there it ranks in the 26th percentile.
GILD Stock Summary
- GILEAD SCIENCES INC's market capitalization of $98,603,230,065 is ahead of 97.88% of US-listed equities.
- With a one year PEG ratio of 88.54, GILEAD SCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 76.01% of US stocks.
- GILD's went public 31.36 years ago, making it older than 84.55% of listed US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to GILEAD SCIENCES INC, a group of peers worth examining would be ADI, GSK, AMGN, BA, and ATVI.
- GILD's SEC filings can be seen here. And to visit GILEAD SCIENCES INC's official web site, go to www.gilead.com.
GILD Valuation Summary
- GILD's price/earnings ratio is 17.6; this is 26.97% lower than that of the median Healthcare stock.
- Over the past 243 months, GILD's EV/EBIT ratio has gone up 45.4.
Below are key valuation metrics over time for GILD.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
GILD | 2023-05-23 | 3.6 | 4.7 | 17.6 | 14.4 |
GILD | 2023-05-22 | 3.6 | 4.7 | 17.6 | 14.4 |
GILD | 2023-05-19 | 3.6 | 4.7 | 17.6 | 14.4 |
GILD | 2023-05-18 | 3.6 | 4.6 | 17.5 | 14.3 |
GILD | 2023-05-17 | 3.6 | 4.7 | 17.6 | 14.4 |
GILD | 2023-05-16 | 3.6 | 4.7 | 17.5 | 14.3 |
GILD Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at -60.73%.
- Its 5 year net cashflow from operations growth rate is now at -41.74%.
- The 5 year net income to common stockholders growth rate now stands at -60.73%.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 27,281 | 9,072 | 4,592 |
2022-09-30 | 27,136 | 9,710 | 3,334 |
2022-06-30 | 27,515 | 10,100 | 4,137 |
2022-03-31 | 27,472 | 10,614 | 4,515 |
2021-12-31 | 27,305 | 11,384 | 6,225 |
2021-09-30 | 27,482 | 10,095 | 7,394 |
GILD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
- GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
- ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.
The table below shows GILD's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.406 | 0.805 | 0.259 |
2021-06-30 | 0.402 | 0.801 | 0.179 |
2021-03-31 | 0.405 | 0.806 | 0.066 |
2020-12-31 | 0.403 | 0.815 | 0.058 |
2020-09-30 | 0.389 | 0.790 | 0.058 |
2020-06-30 | 0.375 | 0.786 | 0.009 |
GILD Price Target
For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $75.84 | Average Broker Recommendation | 1.7 (Moderate Buy) |
Gilead Sciences Inc. (GILD) Company Bio
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).
Latest GILD News From Around the Web
Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.
How To Trade Stocks: Do You Know The Seven Most Important Words On Wall Street?Want to learn how to trade stocks successfully? First examine fundamentals. And keep these seven key words on Wall Street in mind. |
Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the companyKey Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to... |
3 Relatively Safe Stocks to Buy if a Recession Is on the WayHere's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now. |
3 Analyst Upgrades That Smart Investors Won’t IgnoreEven the most experienced investors have only so many hours in the day to perform their due diligence. |
Former Immunomedics CFO pleads guilty to insider tradingThe former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time. Usama Malik, 48, former CFO of Immunomedics Inc, now owned by Gilead Sciences Inc, admitted to a single charge of securities fraud at a hearing before U.S. District Judge John Michael Vazquez in Newark, New Jersey. |
GILD Price Returns
1-mo | -6.23% |
3-mo | -3.36% |
6-mo | -10.66% |
1-year | 24.00% |
3-year | 12.40% |
5-year | 38.77% |
YTD | -9.35% |
2022 | 23.63% |
2021 | 29.95% |
2020 | -6.70% |
2019 | 7.88% |
2018 | -9.92% |
GILD Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching GILD
Want to do more research on Gilead Sciences Inc's stock and its price? Try the links below:Gilead Sciences Inc (GILD) Stock Price | Nasdaq
Gilead Sciences Inc (GILD) Stock Quote, History and News - Yahoo Finance
Gilead Sciences Inc (GILD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...